SignalChem Diagnostics provides a specialized selection of COVID-19 inhibitors, designed to support innovative research in antiviral therapies and drug discovery. Our curated portfolio features a range of compounds with demonstrated potential in targeting various aspects of the SARS-CoV-2 replication cycle or modulating host immune responses. These high-purity inhibitors enable researchers to investigate the efficacy, safety, and mechanism of action of potential therapeutic candidates.
| Name | Catalog Number | CAS Registration Number | Molecular Formula |
| ACE2 (18-615) Protein | A51C2-G342F | ||
| Bafilomycin A1 | V115-905 | 88899-55-2 | C35H58O9 |
| Camostat Mesilate | S565-906 | 59721-29-8 | C20H22N4O5 • CH3SO3H |
| Captopril | A51-906 | 62571-86-2 | C9H15NO3S |
| Chloroquine phosphate | C119-905 | 50-63-5 | C18H26ClN3 · 2H3PO4 |
| Hydroxychloroquine | T860-905 | 747-36-4 | C18H26ClN3O · H2SO4 |
| INK-128 | F17-901C | C15H15N7O | |
| Losartan potassium | S35-908 | 124750-99-8 | C22H22ClN6O · K |
| Mycophenolic acid | I23-905 | 24280-93-1 | C17H20O6 |
| Niclosamide | S54-900 | 50-65-7 | C13H8Cl2N2O4 |
| Nitazoxanide | P312-905 | 55981-09-4 | C12H9N3O5S |
| Ponatinib | A03-900 | 943319-70-8 | C29H27F3N6O |
| RVX-208 | B17-905B | 1044870-39-4 | C20H22N2O5 |
| Tofacitinib | J01-900 | 477600-75-2 | C16H20N6O |
| Valinomycin | V113-908 | 2001-95-8 | C54H90N6O18 |
| Verapamil HCl | V114-908 | 152-11-4 | C27H38N2O4 · HCl |
